Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PQ Birch in Seasonal Allergic Rhinitis/Rhinoconjunctivitis
2023-507427-28-00Phase 3Authorised
- Sponsor
- Allergy Therapeutics PLC
- Start
- Oct 2024
- Modality
- Peptide-based Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in seasonal allergic rhinitis (SAR) and seasonal allergic conjunctivitis (SAC) comparing Pollinex Quattro Plus Birch with Placebo (2 arms). Primary endpoint: Combined Symptom and Medication Score (CSMS) averaged over the peak birch pollen season (BPS). Planned start Oct 2024; status: authorised.
02
Drugs
depigoid birch
03
Conditions
seasonal allergic rhinitis (SAR)seasonal allergic conjunctivitis (SAC)
Beyond the preview
Go deeper on 2023-507427-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507427-28-00.